CD160 receptor in CLL: Current state and future avenues

Overview of attention for article published in Frontiers in immunology, November 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 52,546 followers.

Check out our paper on CD160 receptor in chronic lymphocytic leukemia in @FrontiersinImmunology

07 Jan 2023

Reply Repost Favourite

CD160 receptor in CLL: Current state and future avenues by Loubna Oumeslakht https://t.co/64e90N16BA

24 Nov 2022

Reply Repost Favourite

CD160 receptor in CLL: Current state and future avenues https://t.co/61WhOwlVSY https://t.co/7iUq50EGIu

08 Nov 2022

Reply Repost Favourite

New Research: CD160 receptor in CLL: Current state and future avenues: CD160 is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein expressed on cytotoxic natural killer (NK) cells and T-cell subsets. It plays a crucial… https://t.co/Sz

07 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.